Benzinga | Aug 12, 2020 04:21PM EDT

Cyclacel Pharmaceuticals Q2 EPS $(0.58) Misses $(0.47) Estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.47) by 23.4 percent. This is a 72.77 percent increase over losses of $(2.13) per share from the same period last year.